Immunicum announces that a patent application in China regarding the Company's CD70-technology will be granted



Gothenburg, Sweden, July 26, 2016. Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that the Chinese Patent Office (SIPO) intends to grant a patent relating to the Company’s CD70-technology.

– We are pleased with the positive news from the Chinese Patent Office, SIPO, which gives us important protection for our CD70-technology, says Jamal El-Mosleh, CEO of Immunicum.

The Chinese patent to be granted, with the titel “Method for proliferation of antigen-specific T cells“, protects the method for expansion of tumor specific T cells for so called adoptive immunotherapy with CAR T cells.

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com

The Company’s Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se

About Immunicum AB (publ)

Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company’s most advanced product – INTUVAX® against kidney cancer – has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST).
www.immunicum.com

Keep reading

Immunicum submits IND application to the Food and Drug Administration (FDA) for approval to treat kidney cancer patients in the United States in its ongoing phase II-trial